Novavax (NVAX) Net Cash Flow Growth (1y) (2011 - 2026)
Novavax (NVAX) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Novavax | 1.23 Bn | 440.77 Mn | 108.82 Mn | 91.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91.32% |
| Dec 31, 2025 | 21.43% |
| Sep 30, 2025 | 112.17% |
| Jun 30, 2025 | -108.73% |
| Mar 31, 2025 | -213.10% |
| Dec 31, 2024 | 61.88% |
| Sep 30, 2024 | -181.25% |
| Jun 30, 2024 | 268.76% |
| Mar 31, 2024 | 87.93% |
| Dec 31, 2023 | -265.77% |
| Sep 30, 2023 | 240.19% |
| Jun 30, 2023 | 37.96% |
| Mar 31, 2023 | -1,390.19% |
| Dec 31, 2022 | 112.29% |
| Sep 30, 2022 | 41.66% |
| Jun 30, 2022 | -305.92% |
| Mar 31, 2022 | -96.05% |
| Dec 31, 2021 | -271.27% |
| Sep 30, 2021 | -31.22% |
| Jun 30, 2021 | -73.06% |